$PCVX
Vaxcyte, Inc. Stock $pcvx

$pcvx Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024021145 Filed on February 27, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$42.44M	$17.53M	$125.0M
YoY Change	62.63%	-24.89%	69.83%
% of Gross Profit
Research & Development	$94.59M	$104.2M	$332.3M
YoY Change	62.86%	158.8%	96.13%
% of Gross Profit
Depreciation & Amortization	$999.0K	$888.0K	$3.156M
YoY Change	40.31%	26.5%	22.47%
% of Gross Profit
Operating Expenses	$114.5M	$121.7M	$468.0M
YoY Change	60.79%	91.38%	101.52%
Operating Profit	-$114.5M		-$468.0M
YoY Change	60.79%		101.52%
Interest Expense	$19.33M	$15.87M	$0.00
YoY Change	91.8%	107.66%	-100.0%
% of Operating Profit
Other Income/Expense, Net	$19.45M	$6.000K	$65.78M
YoY Change	81.29%	-99.35%	649.91%
Pretax Income	-$95.02M	-$180.8M	-$402.3M
YoY Change	57.16%	131.65%	80.0%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$95.02M	-$180.8M	-$402.3M
YoY Change	57.16%	131.65%	80.0%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.85		-$4.14
Diluted Earnings Per Share	-$0.85	-$1.76	-$4.14
COMMON SHARES
Basic Shares Outstanding	108.4M	95.15M	97.16M
Diluted Shares Outstanding	111.7M shares		97.16M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.487B	$1.080B	$1.080B
YoY Change	80.83%	15.98%	15.98%
Cash & Equivalents	$611.5M	$397.5M	$397.5M
Short-Term Investments	$875.0M	$682.8M	$682.8M
Other Short-Term Assets	$2.092M	$2.105M	$15.73M
YoY Change	-88.77%	-81.17%	40.68%
Inventory
Prepaid Expenses	$7.774M	$6.159M
Receivables
Other Receivables
Total Short-Term Assets	$1.517B	$1.096B	$1.096B
YoY Change	80.46%	16.27%	16.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$84.84M	$79.63M	$110.6M
YoY Change	457.94%	668.59%	249.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$413.2M	$162.7M	$162.7M
YoY Change	223.32%	512.73%	512.73%
Other Assets	$46.14M	$37.56M	$38.67M
YoY Change	1071.14%	724.63%	612.59%
Total Long-Term Assets	$574.2M	$312.0M	$312.0M
YoY Change	242.85%	390.33%	390.33%
TOTAL ASSETS
Total Short-Term Assets	$1.517B	$1.096B	$1.096B
Total Long-Term Assets	$574.2M	$312.0M	$312.0M
Total Assets	$2.091B	$1.408B	$1.408B
YoY Change	107.44%	39.93%	39.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$21.72M	$14.59M	$14.59M
YoY Change	86.97%	48.92%	48.92%
Accrued Expenses	$54.17M	$59.82M	$130.8M
YoY Change	195.19%	289.04%	325.48%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$87.10M	$145.3M	$145.3M
YoY Change	65.14%	258.64%	258.64%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$20.22M	$0.00	$22.11M
YoY Change	288728.57%	-100.0%	83.65%
Total Long-Term Liabilities	$20.22M	$0.00	$22.11M
YoY Change	288728.57%	-100.0%	83.65%
TOTAL LIABILITIES
Total Short-Term Liabilities	$87.10M	$145.3M	$145.3M
Total Long-Term Liabilities	$20.22M	$0.00	$22.11M
Total Liabilities	$107.3M	$167.4M	$167.4M
YoY Change	69.3%	218.56%	218.56%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.019B	-$924.4M
YoY Change	74.98%	77.04%
Common Stock	$3.001B	$2.165B
YoY Change	96.46%	46.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.984B	$1.240B	$1.240B
YoY Change
Total Liabilities & Shareholders Equity	$2.091B	$1.408B	$1.408B
YoY Change	107.44%	39.93%	39.93%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$95.02M	-$180.8M	-$402.3M
YoY Change	57.16%	131.65%	80.0%
Depreciation, Depletion And Amortization	$999.0K	$888.0K	$3.156M
YoY Change	40.31%	26.5%	22.47%
Cash From Operating Activities	-$159.1M	-$128.8M	-$296.8M
YoY Change	233.66%	97.5%	73.97%
INVESTING ACTIVITIES
Capital Expenditures	$5.678M	$57.07M	$16.06M
YoY Change	1.23%	4875.5%	174.66%
Acquisitions
YoY Change
Other Investing Activities	-$439.0M	$43.14M	-$705.4M
YoY Change	-0.79%	-223.96%	-977.05%
Cash From Investing Activities	-$451.1M	-$13.93M	-$773.3M
YoY Change	0.66%	-61.27%	-1136.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$90.74M
YoY Change			-6.74%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$818.2M	2.735M	639.8M
YoY Change	1868.62%	-99.58%	-25.74%
NET CHANGE
Cash From Operating Activities	-$159.1M	-128.8M	-296.8M
Cash From Investing Activities	-$451.1M	-13.93M	-773.3M
Cash From Financing Activities	$818.2M	2.735M	639.8M
Net Change In Cash	$214.1M	-140.0M	-437.0M
YoY Change	-147.13%	-125.2%	-157.07%
FREE CASH FLOW
Cash From Operating Activities	-$159.1M	-$128.8M	-$296.8M
Capital Expenditures	$5.678M	$57.07M	$16.06M
Free Cash Flow	-$164.8M	-$185.9M	-$312.9M
YoY Change	209.2%	180.07%	77.31%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	ecd	Trd Arr Duration TrdArrDuration	P1Y3M15D
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001649094
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	pcvx	Automatic Renewal Period AutomaticRenewalPeriod	P3Y
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39323
CY2023	dei	Entity Registrant Name EntityRegistrantName	VAXCYTE, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-4233385
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	825 Industrial Road
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	San Carlos
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94070
CY2023	dei	City Area Code CityAreaCode	650
CY2023	dei	Local Phone Number LocalPhoneNumber	837-0111
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2023	dei	Trading Symbol TradingSymbol	PCVX
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	4100000000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	108407730
CY2023	dei	Auditor Firm AuditorFirmId	34
CY2023	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2023	dei	Auditor Location AuditorLocation	San Francisco, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	397451000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	834657000
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	682776000
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	96719000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15727000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11179000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1095954000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	942555000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	79626000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10360000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	30997000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21288000
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	162675000
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	26549000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1103000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	871000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	37562000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4555000
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	311963000
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	63623000
CY2023Q4	us-gaap	Assets Assets	1407917000
CY2022Q4	us-gaap	Assets Assets	1006178000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	14587000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9795000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11056000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1180000
CY2023Q4	pcvx	Accrued Manufacturing Expenses AccruedManufacturingExpenses	52767000
CY2022Q4	pcvx	Accrued Manufacturing Expenses AccruedManufacturingExpenses	8265000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	59815000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15375000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7113000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5910000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	145338000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	40525000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	22111000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12031000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9000
CY2023Q4	us-gaap	Liabilities Liabilities	167449000
CY2022Q4	us-gaap	Liabilities Liabilities	52565000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	95364831
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	95364831
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	79470670
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	79470670
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	98000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	82000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2164583000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1476018000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	179000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-361000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-924392000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-522126000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1240468000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	953613000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1407917000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1006178000
CY2023	pcvx	Research And Development Expense To Related Party ResearchAndDevelopmentExpenseToRelatedParty	0
CY2022	pcvx	Research And Development Expense To Related Party ResearchAndDevelopmentExpenseToRelatedParty	0
CY2021	pcvx	Research And Development Expense To Related Party ResearchAndDevelopmentExpenseToRelatedParty	2359000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	332341000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	169451000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	78411000
CY2023	pcvx	Acquired Manufacturing Rights AcquiredManufacturingRights	75000000
CY2022	pcvx	Acquired Manufacturing Rights AcquiredManufacturingRights	22995000
CY2021	pcvx	Acquired Manufacturing Rights AcquiredManufacturingRights	0
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	60700000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	39810000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25259000
CY2023	us-gaap	Operating Expenses OperatingExpenses	468041000
CY2022	us-gaap	Operating Expenses OperatingExpenses	232256000
CY2021	us-gaap	Operating Expenses OperatingExpenses	103670000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-468041000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-232256000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-103670000
CY2023	us-gaap	Interest Expense InterestExpense	0
CY2022	us-gaap	Interest Expense InterestExpense	2000
CY2021	us-gaap	Interest Expense InterestExpense	7000
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	62907000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	8356000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	344000
CY2023	pcvx	Grant Income GrantIncome	4765000
CY2022	pcvx	Grant Income GrantIncome	1931000
CY2021	pcvx	Grant Income GrantIncome	1585000
CY2023	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0
CY2022	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0
CY2021	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	2000
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-44000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1897000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1470000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1669000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	65775000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8771000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3593000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-402266000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-223485000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-100077000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.14
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.14
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.44
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.44
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.93
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.93
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97157690
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97157690
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	64877988
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51922108
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51922108
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-402266000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-223485000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-100077000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	538000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-120000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-241000
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-401726000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-223605000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-100318000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	345843000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3012000
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	10001000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	888000
CY2021	pcvx	Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions	16000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10729000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-241000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-100077000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	284018000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4895000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1033000
CY2022	pcvx	Release Of Restricted Stock Units Value ReleaseOfRestrictedStockUnitsValue	861000
CY2022	pcvx	Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions	8000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23650000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-120000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-223485000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	953613000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5608000
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2038000
CY2023	pcvx	Release Of Restricted Stock Units Value ReleaseOfRestrictedStockUnitsValue	3876000
CY2023	pcvx	Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions	8000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	48760000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	538000
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-402266000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1240468000
CY2023	us-gaap	Profit Loss ProfitLoss	-402266000
CY2022	us-gaap	Profit Loss ProfitLoss	-223485000
CY2021	us-gaap	Profit Loss ProfitLoss	-100077000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3156000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2577000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1800000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	48760000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	23650000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	10729000
CY2023	pcvx	Non Cash Payments For Acquire Manufacturing Rights NonCashPaymentsForAcquireManufacturingRights	0
CY2022	pcvx	Non Cash Payments For Acquire Manufacturing Rights NonCashPaymentsForAcquireManufacturingRights	7995000
CY2021	pcvx	Non Cash Payments For Acquire Manufacturing Rights NonCashPaymentsForAcquireManufacturingRights	0
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-44000
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-97000
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	213000
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	7015000
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	6619000
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1657000
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	34775000
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	947000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1406000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-17870000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-433000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7369000
CY2023	pcvx	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	16724000
CY2022	pcvx	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	0
CY2021	pcvx	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	0
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	33007000
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	465000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	3539000
CY2023	pcvx	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-11284000
CY2022	pcvx	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1151000
CY2021	pcvx	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	12856000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	11225000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2896000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-12470000
CY2023	pcvx	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	9876000
CY2022	pcvx	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	-2275000
CY2021	pcvx	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	3170000
CY2023	pcvx	Increase Decrease In Accrued Manufacturing Expenses IncreaseDecreaseInAccruedManufacturingExpenses	44501000
CY2022	pcvx	Increase Decrease In Accrued Manufacturing Expenses IncreaseDecreaseInAccruedManufacturingExpenses	3826000
CY2021	pcvx	Increase Decrease In Accrued Manufacturing Expenses IncreaseDecreaseInAccruedManufacturingExpenses	-8572000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	36295000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	7171000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4631000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-296790000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-170597000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-121393000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16062000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5848000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6555000
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1329896000
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	102745000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	336341000
CY2023	pcvx	Payment For Equipment Manufacturing Facility Construction In Progress PaymentForEquipmentManufacturingFacilityConstructionInProgress	51815000
CY2022	pcvx	Payment For Equipment Manufacturing Facility Construction In Progress PaymentForEquipmentManufacturingFacilityConstructionInProgress	0
CY2021	pcvx	Payment For Equipment Manufacturing Facility Construction In Progress PaymentForEquipmentManufacturingFacilityConstructionInProgress	0
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	611876000
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	168691000
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	100500000
CY2023	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	12586000
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	14480000
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	30062000
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	7000
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	26000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-773311000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	74585000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-212308000
CY2023	pcvx	Proceeds From Issuance Of Common Stock And Pre Funded Warrants From Follow On Offerings Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts	545302000
CY2022	pcvx	Proceeds From Issuance Of Common Stock And Pre Funded Warrants From Follow On Offerings Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts	759181000
CY2021	pcvx	Proceeds From Issuance Of Common Stock And Pre Funded Warrants From Follow On Offerings Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts	0
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	90741000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	97299000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13896000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5608000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4895000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3012000
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2038000
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1033000
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	888000
CY2023	pcvx	Release Of Restricted Stock Units Value ReleaseOfRestrictedStockUnitsValue	3876000
CY2022	pcvx	Release Of Restricted Stock Units Value ReleaseOfRestrictedStockUnitsValue	861000
CY2021	pcvx	Release Of Restricted Stock Units Value ReleaseOfRestrictedStockUnitsValue	0
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	639813000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	861547000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17796000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-6686000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	137000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-439000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-436974000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	765672000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-316344000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	835528000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69856000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	386200000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	398554000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	835528000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69856000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	0
CY2022	us-gaap	Interest Paid Net InterestPaidNet	2000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	7000
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	8510000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	110000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	766000
CY2023	pcvx	Issuance Of Common Stock For Acquired Manufacturing Rights IssuanceOfCommonStockForAcquiredManufacturingRights	0
CY2022	pcvx	Issuance Of Common Stock For Acquired Manufacturing Rights IssuanceOfCommonStockForAcquiredManufacturingRights	7995000
CY2021	pcvx	Issuance Of Common Stock For Acquired Manufacturing Rights IssuanceOfCommonStockForAcquiredManufacturingRights	0
CY2023	us-gaap	Stock Issued1 StockIssued1	0
CY2022	us-gaap	Stock Issued1 StockIssued1	0
CY2021	us-gaap	Stock Issued1 StockIssued1	10000000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements. On an ongoing basis, we evaluate our estimates and assumptions, including those related to stock-based compensation expense, accruals for certain research and development costs, the incremental borrowing rate, the valuation of deferred tax assets and income taxes. Management bases our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject us to a concentration of credit risk consist primarily of cash, cash equivalents and investments. We invest in money market funds, U.S. Treasury securities, U.S. government agency securities, corporate debt, commercial paper and asset-backed securities. We maintain bank deposits in federally insured financial institutions and these deposits may exceed federally insured limits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash and issuers of investments to the extent recorded on the consolidated balance sheets. For example, on March 10, 2023, the California Department of Financial Protection and Innovation took control of Silicon Valley Bank (“SVB”) and appointed the Federal Deposit Insurance Corporation (“FDIC”) as receiver. While SVB was our primary bank at the time, we maintained banking relationships with other major banks. The substantial majority of funds we held at</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SVB, which included cash, cash equivalents and investments, were held in custodial accounts of a third-party institution for which SVB Asset Management was the advisor (“SVB Custodial Accounts”). On March 12, 2023, the FDIC confirmed that depositors of SVB would have access to all of their money and, as a result, we regained access to all of our funds deposited with SVB. The FDIC subsequently transferred SVB’s deposits and loans to a newly created bridge bank, named Silicon Valley Bridge Bank, N.A. (“Silicon Valley Bridge Bank”). On March 26, 2023, the FDIC announced that First Citizens Bank & Trust Company (“First Citizens Bank”) had agreed to purchase and assume all deposits and loans of Silicon Valley Bridge Bank. We have not experienced any losses on these deposits or investments as a result of this market event. While we were able to recover all deposited amounts from SVB, and continue to have access to all investments held in the SVB Custodial Accounts, there can be no assurance that our current or future banks will not face similar risks as SVB or that we will be able to recover in full our deposits in the event of similar closures. Our investment policy limits investments to money market funds, certain types of debt securities issued by the U.S. Government and its agencies, corporate debt, commercial paper and asset-backed securities, and places restrictions on the credit ratings, maturities and concentration by type and issuer. We have not experienced any significant losses on our deposits of cash, cash equivalents or investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to supplier concentration risk from certain vendors. Although we are working to establish secondary sources of supply, we currently source several of our critical raw materials from single-source suppliers. We also use one contract manufacturing organization (“CMO”), Lonza Ltd. (“Lonza”), to handle most of our manufacturing activities for our VAX-24 and VAX-31 programs. If we were to experience disruptions in raw materials supplied by our suppliers, or in manufacturing activities at Lonza, we may experience significant delays in our product development timelines and may incur substantial costs to secure alternative sources of raw materials or manufacturing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future results of operations involve a number of other risks and uncertainties. Factors that could affect our future operating results and cause actual results to vary materially from expectations include, but are not limited to: our early stages of clinical vaccine development; our ability to advance vaccine candidates into, and successfully complete, clinical trials on the timelines we project; our ability to adequately demonstrate sufficient safety and immunogenicity or efficacy of our vaccine candidates; our ability to enroll subjects in our ongoing and future clinical trials; our ability to successfully manufacture and supply our vaccine candidates for clinical trials or for future potential commercialization; our ability to obtain additional capital to finance our operations; our ability to obtain, maintain and protect our intellectual proper</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ty rights; developments relating to our competitors and our industry, including competing vaccine candidates; general and market conditions; and other risks and uncertainties, including those more fully described in the “Risk Factors” section of this Annual Report on Form 10-K.</span></p>
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	397451000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	834657000
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	1103000
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	871000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	398554000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	835528000
CY2023	pcvx	Number Of Finance Lease NumberOfFinanceLease	0
CY2022	pcvx	Number Of Finance Lease NumberOfFinanceLease	0
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	200000
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	682776000
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	162675000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	845451000
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6159000
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5312000
CY2023Q4	pcvx	Purchased Equipment Deposits Current PurchasedEquipmentDepositsCurrent	3856000
CY2022Q4	pcvx	Purchased Equipment Deposits Current PurchasedEquipmentDepositsCurrent	0
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	3598000
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	2848000
CY2023Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	9000
CY2022Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	1029000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2105000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1990000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15727000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11179000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	88898000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16477000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9272000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6117000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	79626000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10360000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3200000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2600000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1800000
CY2023Q4	pcvx	Manufacturing Facility Construction Build Out ManufacturingFacilityConstructionBuildOut	34688000
CY2022Q4	pcvx	Manufacturing Facility Construction Build Out ManufacturingFacilityConstructionBuildOut	0
CY2023Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	2768000
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	4361000
CY2023Q4	pcvx	Other Long Term Assets OtherLongTermAssets	106000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y8M15D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M10D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.084
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.076
CY2022Q4	pcvx	Other Long Term Assets OtherLongTermAssets	194000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	37562000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4555000
CY2023Q4	pcvx	Clinical Studies ClinicalStudies	2156000
CY2022Q4	pcvx	Clinical Studies ClinicalStudies	1518000
CY2023Q4	pcvx	Other Research And Development Liabilities Current OtherResearchAndDevelopmentLiabilitiesCurrent	30759000
CY2022Q4	pcvx	Other Research And Development Liabilities Current OtherResearchAndDevelopmentLiabilitiesCurrent	7446000
CY2023Q4	pcvx	Acquired Manufacturing Rights Current AcquiredManufacturingRightsCurrent	25000000
CY2022Q4	pcvx	Acquired Manufacturing Rights Current AcquiredManufacturingRightsCurrent	5000000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1900000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1411000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	59815000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15375000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	7390000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	5374000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	30997000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21288000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7113000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5910000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	22111000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12031000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	29224000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	17941000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	95364831
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	95364831
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	79470670
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	79470670
CY2023	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2022	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	8817000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	9836000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2899000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2986000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3075000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	9503000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	37115000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7891000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	29224000
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	8500000
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	7900000
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	3200000
CY2023Q4	pcvx	Noncancelable Purchase Commitments Due In One Year NoncancelablePurchaseCommitmentsDueInOneYear	181812000
CY2023Q4	pcvx	Non Cancelable Purchase Commitments Due In Second Year NonCancelablePurchaseCommitmentsDueInSecondYear	41840000
CY2023Q4	pcvx	Non Cancelable Purchase Commitments Due In Third Year NonCancelablePurchaseCommitmentsDueInThirdYear	1296000
CY2023Q4	pcvx	Non Cancelable Purchase Commitments Due In Four Year NonCancelablePurchaseCommitmentsDueInFourYear	414000
CY2023Q4	pcvx	Non Cancelable Purchase Commitments NonCancelablePurchaseCommitments	225362000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023	us-gaap	Preferred Stock Dividends Per Share Cash Paid PreferredStockDividendsPerShareCashPaid	0
CY2023	us-gaap	Preferred Stock Dividends Per Share Declared PreferredStockDividendsPerShareDeclared	0
CY2022	us-gaap	Preferred Stock Dividends Per Share Cash Paid PreferredStockDividendsPerShareCashPaid	0
CY2022	us-gaap	Preferred Stock Dividends Per Share Declared PreferredStockDividendsPerShareDeclared	0
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2023	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Each share of common stock is entitled to one vote
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	36710
CY2022Q1	pcvx	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right Exercised ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised	0.001
CY2022Q4	pcvx	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right Exercised ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised	0.001
CY2023Q2	pcvx	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right Exercised ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised	0.001
CY2022Q1	pcvx	Increase Or Decrease Of Pre Funded Warrant Percentage Not Exceed IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed	0.1999
CY2022Q4	pcvx	Increase Or Decrease Of Pre Funded Warrant Percentage Not Exceed IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed	0.1999
CY2023Q2	pcvx	Increase Or Decrease Of Pre Funded Warrant Percentage Not Exceed IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed	0.1999
CY2023Q4	pcvx	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right Exercised ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised	0
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2020Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.25
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2020Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.25
CY2023Q4	pcvx	Early Exercised Stock Options EarlyExercisedStockOptions	0
CY2022Q4	pcvx	Early Exercised Stock Options EarlyExercisedStockOptions	3705
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	36710
CY2023	pcvx	Number Of Options Exercised Excludes Options Exercised From Npln NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln	538888
CY2022	pcvx	Number Of Options Exercised Excludes Options Exercised From Npln NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln	1153285
CY2021	pcvx	Number Of Options Exercised Excludes Options Exercised From Npln NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln	926514
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	10.5
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.25
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.25
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	28.74
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	18.88
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14.65
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	21200000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.74
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.781
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.851
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.81
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.841
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	34000000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	18900000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	0
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	581047
CY2022	pcvx	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted	26250
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	79229
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	24790
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	45052
CY2022	pcvx	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Cancelled ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueCancelled	24320
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	456766
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested	26700
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	574123
CY2023	pcvx	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted	45570
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	232890
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	30970
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	44537
CY2023	pcvx	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Cancelled ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueCancelled	40780
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	753462
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested	38930
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.713
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51922108
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.14
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.14
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.44
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.035
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.046
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.016
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.044
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.005
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.013
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	127500000
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M12D
CY2023	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	1400000
CY2022	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	800000
CY2021	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	0
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-402266000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-223485000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-100077000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97157690
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97157690
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	64877988
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	64877988
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51922108
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.44
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.93
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.93
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10208636
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8322210
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5423793
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.005
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.015
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.022
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.014
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.008
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.011
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.218
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.213
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.23
CY2023	pcvx	Section162 M Limitation Section162MLimitation	-0.011
CY2022	pcvx	Section162 M Limitation Section162MLimitation	-0.018
CY2021	pcvx	Section162 M Limitation Section162MLimitation	-0.011
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	135298000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	111555000
CY2023	pcvx	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	485000
CY2022	pcvx	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	-46000
CY2021	pcvx	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	70000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4447000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1754000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	924000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	461000
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	660000
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1062000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	11279000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	1103000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	12870000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	5436000
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	79485000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	32873000
CY2023Q4	pcvx	Deferred Tax Assets Tax Accrued Manufacturing Expenses DeferredTaxAssetsTaxAccruedManufacturingExpenses	10819000
CY2022Q4	pcvx	Deferred Tax Assets Tax Accrued Manufacturing Expenses DeferredTaxAssetsTaxAccruedManufacturingExpenses	2063000
CY2023Q4	pcvx	Lease Liability LeaseLiability	8739000
CY2022Q4	pcvx	Lease Liability LeaseLiability	5358000
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	29302000
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	6867000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	8981000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4474000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	297434000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	170791000
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	9269000
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	6357000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	9269000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	6357000
CY2023Q4	pcvx	Deferred Tax Assets Liabilities Net Before Valuation Allowance DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance	288165000
CY2022Q4	pcvx	Deferred Tax Assets Liabilities Net Before Valuation Allowance DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance	164433000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	288165000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	164433000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4400000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1800000
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1754000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	924000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	393000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2208000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	876000
CY2023Q4	ecd	Trd Arr Ind Name TrdArrIndName	Elvia Cowan
CY2023Q4	ecd	Trd Arr Ind Title TrdArrIndTitle	Senior Vice President of Finance and Principal Accounting Officer
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	true
CY2023Q4	ecd	Trd Arr Adoption Date TrdArrAdoptionDate	November 13, 2023
CY2023Q4	ecd	Trd Arr Securities Agg Avail Amt TrdArrSecuritiesAggAvailAmt	26678
CY2023Q4	ecd	Trd Arr Termination Date TrdArrTerminationDate	February 28, 2025

Files In Submission

Name	View Source	Status
0000950170-24-021145-index-headers.html	Edgar Link	pending
0000950170-24-021145-index.html	Edgar Link	pending
0000950170-24-021145.txt	Edgar Link	pending
0000950170-24-021145-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img153871529_0.jpg	Edgar Link	pending
img71475350_0.jpg	Edgar Link	pending
img71475350_1.jpg	Edgar Link	pending
img71475350_10.jpg	Edgar Link	pending
img71475350_11.jpg	Edgar Link	pending
img71475350_12.jpg	Edgar Link	pending
img71475350_13.jpg	Edgar Link	pending
img71475350_14.jpg	Edgar Link	pending
img71475350_15.jpg	Edgar Link	pending
img71475350_16.jpg	Edgar Link	pending
img71475350_17.jpg	Edgar Link	pending
img71475350_18.jpg	Edgar Link	pending
img71475350_19.jpg	Edgar Link	pending
img71475350_2.jpg	Edgar Link	pending
img71475350_20.jpg	Edgar Link	pending
img71475350_21.jpg	Edgar Link	pending
img71475350_22.jpg	Edgar Link	pending
img71475350_23.jpg	Edgar Link	pending
img71475350_24.jpg	Edgar Link	pending
img71475350_25.jpg	Edgar Link	pending
img71475350_26.jpg	Edgar Link	pending
img71475350_27.jpg	Edgar Link	pending
img71475350_28.jpg	Edgar Link	pending
img71475350_29.jpg	Edgar Link	pending
img71475350_3.jpg	Edgar Link	pending
img71475350_30.jpg	Edgar Link	pending
img71475350_31.jpg	Edgar Link	pending
img71475350_4.jpg	Edgar Link	pending
img71475350_5.jpg	Edgar Link	pending
img71475350_6.jpg	Edgar Link	pending
img71475350_7.jpg	Edgar Link	pending
img71475350_8.jpg	Edgar Link	pending
img71475350_9.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pcvx-20231231.htm	Edgar Link	pending
pcvx-20231231.xsd	Edgar Link	pending
pcvx-ex10_12.htm	Edgar Link	pending
pcvx-ex10_14.htm	Edgar Link	pending
pcvx-ex10_19.htm	Edgar Link	pending
pcvx-ex10_21.htm	Edgar Link	pending
pcvx-ex10_23.htm	Edgar Link	pending
pcvx-ex10_26.htm	Edgar Link	pending
pcvx-ex10_27.htm	Edgar Link	pending
pcvx-ex21_1.htm	Edgar Link	pending
pcvx-ex23_1.htm	Edgar Link	pending
pcvx-ex31_1.htm	Edgar Link	pending
pcvx-ex31_2.htm	Edgar Link	pending
pcvx-ex32_1.htm	Edgar Link	pending
pcvx-ex97_1.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pcvx-20231231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PCVX
Vaxcyte, Inc. Stock $pcvx

2024 Q1 Form 10-K Financial Statement

#000095017024021145 Filed on February 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCVX Vaxcyte, Inc. Stock $pcvx

2024 Q1 Form 10-K Financial Statement

#000095017024021145 Filed on February 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCVX
Vaxcyte, Inc. Stock $pcvx